Rakovina Therapeutics Expands Strategic Engagement with Renowned AI Drug Discovery Pioneer Dr. Artem Cherkasov

On November 12, 2026 Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, reported an expanded strategic advisory engagement with Dr. Artem (Art) Cherkasov, PhD, an existing member of the Company’s Scientific Advisory Board (SAB).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Cherkasov, an internationally recognized pioneer in computational drug discovery, artificial intelligence and precision cancer therapeutics, will continue to serve on Rakovina’s Scientific Advisory Board while taking on a more active role as Advisor AI Drug Discovery supporting the Company’s evaluation of new AI technologies, advancement of its discovery programs and pursuit of strategic partnerships.

Dr. Cherkasov’s expanded role fits closely with Rakovina’s AI strategy, which has three elements: strengthening the Company’s relationships with leading AI drug-discovery platforms, including securing exclusivity in its DNA-damage response (DDR) field; using multiple AI platforms, each specialized for different aspects of biochemistry and drug development, rather than relying on a single tool; and considering strategic alternatives, including mergers and acquisitions, that could add technologies, programs or scale.

Rakovina has been executing this strategy. On November 10, 2026, the Company announced an exclusive, worldwide and perpetual licence for DDR oncology drug discovery to the Artemis.AI platform, which incorporates Dr. Cherkasov’s Deep Docking technology, from Artemis Therapeutics Inc. ("Artemis"), where Dr. Cherkasov is a co-founder and Chief Technology Officer. On October 14, 2026, Rakovina announced that it had secured exclusivity over the optimized target product profile for its kt-5000 ATR inhibitor program from Variational AI Inc. ("Variational AI"), and on October [22], 2026, it reported that the kt-5000AI program, designed using Variational AI’s Enki generative AI platform, is advancing toward development candidate selection. On October 1, 2026, Rakovina announced a collaboration with Boston-based Celvion Therapeutics ("Celvion") to apply Celvion’s EMphora AI platform to real-world clinical data for its ATR inhibitor program, and on October 28, 2026, the companies reported the results of their first analysis. These news releases are available on the Company’s website at www.rakovinatherapeutics.com and on SEDAR+ at www.sedarplus.ca.

"Our strategy is to build the strongest position we can in AI-enabled DDR drug discovery: exclusive access to the best platforms in our field, the flexibility to apply the right specialized AI to each problem, and openness to strategic transactions that can accelerate our growth," said Kim Oishi, Chief Executive Officer of Rakovina Therapeutics. "Art has been using AI to accelerate drug discovery for more than 20 years and has an internationally recognized track record, and few people are better placed to judge which AI technologies will deliver results in the lab. His expanded involvement will help us evaluate emerging technologies, deepen our AI partnerships and assess corporate development opportunities as we execute our growth strategy."

A World-class Scientific Leader with a Track Record of Commercial Innovation

Dr. Cherkasov is a Professor in the Department of Urologic Sciences at the University of British Columbia (UBC), a Tier 1 Canada Research Chair in Precision Cancer Drug Design and a Senior Scientist at the Vancouver Prostate Centre.

Over the course of his distinguished career, he has established an exceptional international reputation for applying computational science, machine learning and artificial intelligence to accelerate pharmaceutical discovery and therapeutic innovation.

His accomplishments include:

Pioneer of Deep Docking: Developed the groundbreaking AI-enabled drug discovery platform capable of screening billions of molecular structures against specific biological targets, dramatically accelerating the identification of potential drug candidates.

Landmark Roche / UBC Pharmaceutical Agreement: His research and computational drug discovery work contributed to a landmark licensing and commercialization agreement between UBC and Roche involving a potential treatment for advanced prostate cancer. Announced in 2015, the agreement included potential milestone payments of up to US$141.7 million, plus royalties, representing one of the most significant pharmaceutical commercialization agreements in UBC’s history.

COVID-19 AI Research Breakthrough: During the pandemic, Dr. Cherkasov led an interdisciplinary research initiative applying Deep Docking to identify potential inhibitors of SARS-CoV-2. Working with NVIDIA, Dell Technologies and UBC Advanced Research Computing, his team computationally screened approximately 40 billion molecular structures in just 19 days, identifying promising candidates for further investigation.

International AI Drug Discovery Recognition: His Deep Docking technology achieved first-place results in two international CACHE drug discovery challenges, including initiatives focused on Parkinson’s disease and COVID-19.

Extensive Intellectual Property and Research Portfolio: Dr. Cherkasov has co-authored more than 200 peer-reviewed scientific publications, contributed to more than 80 patent filings and helped advance eight drug candidates that have been licensed to pharmaceutical companies and commercial partners.

Significant Research Leadership: His work at UBC and the Vancouver Prostate Centre has attracted more than CAD $80 million in research funding, supporting advances in computational drug discovery, molecular modelling, cheminformatics and precision oncology.

Dr. Cherkasov’s career exemplifies the potential of AI to fundamentally transform traditional drug discovery by enabling researchers to explore vastly larger chemical spaces, prioritize promising compounds and accelerate the transition from computational predictions to experimental validation.

"AI and computational approaches are fundamentally changing how we discover and develop new therapeutics, creating significant opportunities to accelerate innovation," said Dr. Art Cherkasov. "Realizing this potential requires the integration of scientific expertise, advanced technologies and strategic collaboration. I am pleased to expand my involvement with Rakovina and look forward to working with the team to strengthen its discovery capabilities, explore new opportunities and help shape the Company’s next phase of growth."

The Company believes that realizing the full potential of AI-driven drug discovery requires more than computational capabilities alone. Rakovina combines expertise in AI-enabled drug design with established wet-laboratory research capabilities and deep experience in oncology drug development, enabling the Company to advance promising AI-generated compounds through experimental validation, biological testing and further preclinical development. This integrated approach positions Rakovina to translate computational discoveries into tangible therapeutic opportunities.

"Art brings exceptional expertise in computational drug discovery that complements Rakovina’s strengths in cancer biology, experimental validation and preclinical drug development," said Dr. Mads Daugaard, President and Chief Scientific Officer of Rakovina Therapeutics. "The true potential of AI-driven drug discovery lies in our ability to translate computational predictions into compounds with demonstrated biological activity and therapeutic potential. By combining Art’s expertise with our established wet-laboratory capabilities and oncology research experience, we see significant opportunities to strengthen our discovery programs and accelerate the advancement of promising new cancer therapeutics."

Securities for Services Arrangement

In connection with his expanded role, the Company has entered into a consulting agreement with Dr. Cherkasov effective November 15, 2026, for a term of up to 24 months (the "Consulting Agreement"). Under the Consulting Agreement, Dr. Cherkasov will continue to serve on the Company’s Scientific Advisory Board and will provide advice on AI-enabled drug discovery and development and scientific and technical due diligence on new AI platforms. The services do not include investor relations, promotional or market-making activities.

Dr. Cherkasov will receive compensation of $160,000 per year, of which $100,000 is payable in cash in equal monthly instalments and $60,000 ($15,000 per quarter) is payable in common shares of the Company ("Shares") under a securities-for-services arrangement in accordance with section 6.2 of TSX Venture Exchange ("TSXV") Policy 4.4 – Security Based Compensation.

Shares will be issued quarterly in arrears, only after the services for the applicable quarter have been provided. The number of Shares for each quarter will be determined after the end of that quarter by dividing $20,000 by a deemed price per Share that will not be less than the Discounted Market Price (as defined in TSXV policies) on the date of determination. No warrants will be issued under the arrangement.

Dr. Cherkasov is Non-Arm’s Length Party of the Company. He is a co-founder, director and Chief Technology Officer of Artemis Therapeutics Inc., which is expected to receive Shares as consideration for the Artemis.AI licence announced on November 10, 2026. The arrangement will not result in the creation of a new Control Person. The issuance of Shares is subject to TSXV acceptance, and the Shares will be subject to a hold period of four months and one day from the date of issuance under applicable securities laws. The Company will issue a news release each quarter disclosing the number of Shares issued under the arrangement.

Joint Webinar

Rakovina Therapeutics will host a joint webinar with Artemis Therapeutics on November 18th at 11:30AM PCT (Vancouver time) to discuss the recently announced collaboration between the two companies. The webinar will feature Mr. Kim Oishi CEO of Rakovina, Mr. Frank Holler, CEO of Artemis and Dr. Artem Cherkasov, Co-Founder and CTO of Artemis.

(Press release, Rakovina Therapeutics, NOV 12, 2026, View Source;utm_medium=rss&utm_campaign=rakovina-therapeutics-expands-strategic-engagement-with-renowned-ai-drug-discovery-pioneer-dr-artem-cherkasov [SID1234674683])

Actinium Pharmaceuticals to Host KOL Webinar on ATNM-400, a First-in-Class HER3-Targeted Alpha Radiotherapy

On November 12, 2026 Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, reported that it will host a key opinion leader (KOL) webinar on Tuesday, December 1, 2026, at 8:00 a.m. ET to discuss the evolving treatment landscape in metastatic castration-resistant prostate cancer (mCRPC) and the potential of ATNM-400, its investigational, first-in-class, HER3-targeted Actinium-225 antibody radioconjugate.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will feature Michael J. Morris, MD, Prostate Cancer Section Head at Memorial Sloan Kettering Cancer Center, who will join members of Actinium’s management team for the discussion. Participants can register for the webinar here.

The webinar will explore the applicability of a HER3-targeted radiotherapeutic across the broad mCRPC population, including those patients with low or negative PSMA expression and those who do not respond to or progress following PSMA-directed treatments. The discussion will also examine the role of HER3 in tumor progression and treatment resistance, the rationale for targeting HER3 with alpha radiotherapy, and the potential role of non-PSMA approaches in the evolving prostate cancer treatment paradigm.

Actinium management will review previously reported findings from ATNM-400’s ongoing first-in-human Phase 1 study, HERACT-PRO-1, including initial data presented at the 2026 European Association of Nuclear Medicine (EANM) Congress. HER3-targeted PET imaging demonstrated tumor uptake and retention through Day 7, with no dose-limiting toxicities, xerostomia or Grade 3/4 hematologic adverse events observed in the initial three-patient cohort at the 1.0 µCi/kg dose level. Dose escalation has advanced to the second dose level of 1.5 µCi/kg and is ongoing. Additionally, further detail on the RADIANZ (Radiolabeled Antibody Distribution In Advanced Neoplasms with Zirconium-89) imaging study to validate ATNM-400’s pan-tumor potential will be discussed. Management will also highlight preclinical findings demonstrating ATNM-400’s activity across prostate cancer models with varying PSMA expression and will review clinical plans for ATNM-400 in prostate cancer and additional solid tumors, including lung, breast, colorectal and ovarian cancers.

A live question-and-answer session will follow the presentations.

Webinar Details

Date: Tuesday, December 1, 2026
Time: 8:00 a.m. Eastern Time
Registration: Here

The live webcast will be accessible through the registration link above. A replay will be available following the event through the Events and Presentations section of Actinium’s website at www.actiniumpharma.com.

About Michael J. Morris, MD

Michael J. Morris, MD, is Prostate Cancer Section Head at Memorial Sloan Kettering Cancer Center and a leading investigator in the development of targeted radiopharmaceuticals for prostate cancer. He helped lead the pivotal Phase 3 VISION trial of lutetium-177–PSMA-617, which supported the initial FDA approval of Pluvicto, and is the lead author of the Phase 3 PSMAfore publication. His expertise spans clinical trial development, molecular imaging and the integration of radiopharmaceuticals into prostate cancer care.

About ATNM-400

ATNM-400 is an investigational antibody radioconjugate that pairs the HER3-targeting monoclonal antibody barecetamab with the alpha-emitting isotope Actinium-225. Its antibody-based design combines antigen-specific targeting with the potential for sustained tumor localization, supporting prolonged delivery of high-energy alpha radiation. Tumor uptake and retention observed through Day 7 with the ⁸⁹Zr-labeled imaging counterpart support this development rationale alongside the approximately 10-day half-life of ²²⁵Ac. The theranostic approach enables noninvasive visualization of antibody distribution to inform therapeutic development. The program is being evaluated in a first-in-human dose-escalation Phase 1 study of ATNM-400 in mCRPC, HERACT-PRO-1, which utlizes Zirconium-89-labeled barecetamab PET imaging to assess tumor targeting, biodistribution and dosimetry. Actinium is also conducting an imaging study, RADIANZ (Radiolabeled Antibody Distribution In Advanced Neoplasms with Zirconium-89) using PET to guide the pan-tumor development of ATNM-400 in various solid tumors outside of prostate cancer.

ATNM-400 is differentiated from PSMA-targeted radiotherapies by its focus on HER3, an antigen implicated in tumor survival and treatment resistance. PSMA-directed approaches include Novartis’ Pluvicto and a broad pipeline of investigational therapies, including Telix Pharmaceuticals’ TLX591-Tx, Clarity Pharmaceuticals’ ⁶⁷Cu-SAR-bisPSMA, Convergent Therapeutics’ CONV01-α, AstraZeneca’s AZD2265 (formerly FPI-2265), Curium’s lutetium-177 zadavotide guraxetan (¹⁷⁷Lu-PSMA-I&T), ARTBIO’s AB001 and AdvanCell’s ADVC001. These programs span small-molecule and antibody-based therapies using beta- or alpha-emitting isotopes. ATNM-400 combines HER3 targeting with an Actinium-225 antibody radioconjugate, offering a distinct biological approach with the potential to expand radiotherapy across the broad mCRPC population, including patients with PSMA-low or PSMA-negative disease and those who do not respond to or progress following PSMA-directed treatment. Its HER3-directed mechanism also supports investigation beyond prostate cancer in other HER3-expressing solid tumors.

About HER3

HER3, also known as ERBB3, belongs to the epidermal growth factor receptor family and participates in signaling pathways that promote tumor growth, survival and treatment resistance. HER3-directed antibody-drug conjugates (ADCs) in clinical development include BioNTech and MediLink’s BNT326/YL202; Bristol Myers Squibb and SystImmune’s EGFR × HER3 bispecific ADC, izalontamab brengitecan (iza-bren); and Daiichi Sankyo and Merck’s patritumab deruxtecan (HER3-DXd). These programs highlight clinical development interest in HER3 as an oncology target. ATNM-400 takes a different payload approach, delivering alpha radiation rather than a conventional cytotoxic drug. Preclinical activity in prostate, non-small cell lung, breast, colorectal and ovarian cancer models supports investigating ATNM-400 as a potential pan-cancer radiotherapy, both as monotherapy and in rational combinations.

(Press release, Actinium Pharmaceuticals, NOV 12, 2026, View Source [SID1234674701])

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

On November 12, 2026 Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, reported the closing of its underwritten public offering of 41,071,428 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 5,357,142 additional shares of its common stock, at a public offering price of $3.50 per share. All of the shares of common stock in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $143.7 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies, TD Cowen and Goldman Sachs & Co. LLC acted as joint book-running managers for the offering. Oppenheimer & Co. and LifeSci Capital acted as passive book-running managers for the offering.

The shares of common stock were offered by Prime Medicine pursuant to a shelf registration statement on Form S-3ASR (File No. 333-291348) filed with the U.S. Securities and Exchange Commission (SEC) on November 7, 2025, as amended by that certain Post-Effective Amendment No. 1 to Form S-3 (No. 333-291348) and that certain Post-Effective Amendment No. 2 to Form S-3 (No. 333-291348), each filed with the SEC on March 3, 2026, and declared effective by the SEC on March 4, 2026. The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement relating to and describing the terms of the offering was filed with the SEC and is available on the SEC’s website at www.sec.gov.

Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388, or by email at [email protected]; TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected] or Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at (866) 471-2526, or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

(Press release, Prime Medicine, NOV 12, 2026, View Source [SID1234674718])

First FDA Breakthrough Therapy designation in PSMA PET imaging granted to Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer

On November 12, 2026 Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, reported that the United States (US) Food and Drug Administration (FDA) granted 64Cu-SAR-bisPSMA Breakthrough Therapy designation for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Breakthrough Therapy designation is a process designed to expedite the development and review of drugs that are intended to treat a serious condition, and preliminary clinical evidence indicates that the drug/agent of interest may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s)1. This designation is intended to get promising drugs developed and to the market as quickly and safely as possible, so that they can be available to optimise the treatment of the patients who need them most2. The benefits of a product having Breakthrough Therapy designation include1:

All Fast Track designation features
Intensive guidance on an efficient drug development program
Organisational commitment from the FDA involving senior managers for a more proactive, collaborative, cross-disciplinary review
While Fast Track designation can be granted based on early-stage or nonclinical data, Breakthrough Therapy designation requires preliminary clinical evidence of a treatment effect that may represent considerable additional clinical benefit over available products in a serious condition3. Breakthrough Therapy designation is also a positive indicator of potential eligibility for Priority Review due to overlapping qualifying criteria. Priority Review is requested at the time of the New Drug Application (NDA) submission and can substantially shorten the FDA’s review timeline for an NDA3.

The FDA Breakthrough Therapy designation was supported by data from the Phase II Co-PSMA trial4, Phase I/II COBRA trial5 (see About Co-PSMA and About COBRA sections below) and real-world evidence6, which collectively indicate enhanced diagnostic performance of 64Cu-SAR-bisPSMA over standard-of-care (SOC) PSMA PET in patients with biochemical recurrence (BCR) of prostate cancer.

Clarity is currently progressing two registrational Phase III trials with 64Cu-SAR-bisPSMA, AMPLIFY (NCT06970847)7 and CLARIFY (NCT06056830)8, both of which have successfully completed recruitment and are now in patient follow-up. Topline data from both pivotal trials are anticipated to be released in the first half of calendar year (CY) 2027. As pivotal trials, the final study results are intended to provide sufficient evidence to support an application to the US FDA for approval of 64Cu-SAR-bisPSMA as a new diagnostic imaging agent in prostate cancer patients prior to undergoing definitive therapy (CLARIFY) and with BCR (AMPLIFY).

Dr Alan Taylor, Executive Chairperson of Clarity Pharmaceuticals, commented, "Receiving this Breakthrough Therapy designation is one of the most significant milestones in our prostate cancer program to date. Its importance is further amplified given fewer than half of designation requests across all therapeutic areas are successful9. The FDA’s award of the first Breakthrough Therapy designation in the history of PSMA PET imaging highlights both the unmet need for more accurate detection of recurrent prostate cancer lesions and the significance of the data generated to date, which indicates improved diagnostic performance of 64Cu-SAR-bisPSMA compared to SOC PSMA PET in patients with BCR of prostate cancer.

"Although PSMA PET represents a major advance over conventional imaging for prostate cancer detection, currently approved products miss metastatic disease in many patients, particularly in those with small volume disease. According to their respective FDA-approved prescribing information, the two leading PSMA PET agents demonstrate these limitations across different clinical settings. In initial staging, sensitivities as per the FDA-approved label are 47% for 68Ga-PSMA-1110 and 35% for 18F-DCFPyL11 (averages across readers). In BCR, PET positivity rates on the FDA-approved label are only 36% and 35%, respectively, in patients with PSA<0.5 ng/mL, and only increase to 56% and 50%, respectively, in patients with PSA 0.5 to < 1.0 ng/mL10,11, meaning that disease detection is still missed in up to half the patients even at these higher PSA levels. The Co-PSMA data that had participants with a median PSA level of 0.43 ng/mL and a 68Ga-PSMA-11 detection rate of 36% is comparable to the FDA-approved label. The detection rate for 64Cu-SAR-bisPSMA in Co-PSMA in the same patient group was more than double that of 68Ga-PSMA-11 at 78%4.

"With innovation, scientific rigour and highest standards of clinical development at the core of our Company, our lead product, 64Cu-SAR-bisPSMA, is testament to this approach. Our proprietary sarcophagine (SAR) Technology, derived from the benchtop of Australian science, is a platform technology that enables us to successfully use the ‘perfect pairing’ of copper-64 (for imaging) and copper-67 (for therapy). The potential benefits of copper-64 and copper-67 have been discussed in scientific literature for decades, but their adoption in the clinic had been limited due to issues with copper isotopes leaking from conventional chelators into the body. The SAR Technology is designed to overcome this challenge, opening new opportunities in Targeted Copper Theranostics (TCTs). Being able to successfully employ copper-64 with its longer half-life of 12.7 hours, compared to the gallium-68 and fluorine-18 isotopes with half-lives of 1-2 hours, enables extended imaging timepoints of up to 30 hours post-injection. Differentiating further, we went back to the benchtop and optimised the well-known PSMA target, developing a novel, bivalent bisPSMA agent and subsequently filing a patent for the composition of matter in June 2018, providing us with patent protection until at least 2038. The combination of the secure chelating SAR Technology, optimal imaging timepoints with copper-64 and the bivalent bisPSMA agent is what makes 64Cu-SAR-bisPSMA stand out from the FDA-approved PSMA PET products in the market, with the potential to improve the detection of prostate cancer and facilitate more informed, individualised clinical management in these patients. The longer product shelf-life (compared to Ga-68 and F-18 based products) also translates into supply chain benefits through centralised and regional manufacture as well as broad geographic distribution, which can improve patient access to this important imaging tool.

"The Breakthrough Therapy designation is supported by the Co-PSMA4 and COBRA5 trials as well as real-world evidence6. A key study contributing to this milestone is Co-PSMA, which investigated 64Cu-SAR-bisPSMA against 68Ga-PSMA-11 in a head-to-head and intra-patient comparison design. This investigator-initiated trial (IIT) was conducted by Prof Louise Emmett, a globally renowned nuclear medicine physician, at St Vincent’s Hospital in Sydney. The quality and significance of this work have been recognised globally with the manuscript selected as an Editor’s Choice article by the editors of European Urology, a world-leading clinical journal in the field of Urology with an impressive impact factor of 29.7. The data were showcased at the annual European Association of Urology (EAU) Congress and as a Top-Rated Oral Presentation at the European Association of Nuclear Medicine (EANM) Congress 2026, which underscore the significance of the findings for both the urology and nuclear medicine fields. We are proud to have supported this IIT and are committed to supporting high-quality research involving 64Cu-SAR-bisPSMA in the future.

"The field of PSMA PET imaging has evolved rapidly over the past few years, quickly becoming a blockbuster market with sales of around US$2 billion per year in the US alone, and this is expected to further grow to over US$3 billion by 2029. The substantial and growing PSMA PET market represents a significant opportunity for Clarity, but our ambition extends well beyond market size. Our focus remains firmly on developing products that will improve the outcomes of patients with cancer, and this Breakthrough Therapy designation is an important step in the progress we are making towards this goal.

"We would like to take this opportunity to acknowledge and thank the investigators who have contributed their knowledge, time and resources to the 64Cu-SAR-bisPSMA trials, our team of dedicated and driven individuals who continue tirelessly progressing this program towards launch and, importantly, the participants and their families who took part in our trials and special access cases to date."

About SAR-bisPSMA
SAR-bisPSMA derives its name from the word "bis", which reflects a novel approach of connecting two PSMA-targeting agents to Clarity’s proprietary sarcophagine (SAR) technology that securely holds copper isotopes inside a cage-like structure, called a chelator. Unlike other commercially available chelators, the SAR technology prevents copper leakage into the body. SAR-bisPSMA is a TCT that can be used with isotopes of copper-64 (Cu-64 or 64Cu) for imaging and copper-67 (Cu-67 or 67Cu) for therapy.

About Co-PSMA
Co-PSMA ("Comparative performance of 64Copper [64Cu] SAR-bisPSMA vs. 68Ga-PSMA-11 PET CT for the detection of prostate cancer recurrence in the setting of biochemical failure following radical prostatectomy") was an IIT led by Prof Louise Emmett at St Vincent’s Hospital, Sydney, evaluating the performance of Clarity’s diagnostic product, 64Cu-SAR-bis-PSMA, in a head-to-head comparison to SOC 68Ga-PSMA-11 product in prostate cancer patients with PSA of 0.2 – 0.75 ng/mL. Eligible patients were required to have had radical prostatectomy with no salvage therapy. SOC 68Ga-PSMA-11 PET/CT per institutional protocol was followed by 64Cu-SAR-bisPSMA PET/computed tomography (CT) (at 1 hour and 24 hours post-injection, same-day and next-day imaging, respectively), on the same digital PET camera4.

The primary endpoint of the Co-PSMA study was to assess the difference in mean per patient lesion number. Secondary endpoints included management impact questionnaires between 64Cu-SAR-bisPSMA and 68Ga-PSMA-11 and accuracy of the PET findings determined using a comprehensive reference standard, including biopsy, response to targeted treatment without androgen deprivation therapy (ADT), PSA rise without treatment or corroborative imaging4.

The study enrolled 50 participants (median PSA 0.43 ng/mL [interquartile range: 0.31–0.63]). In addition to meeting its primary endpoint, the study also demonstrated improved diagnostic performance of next-day 64Cu-SAR-bisPSMA PET across multiple parameters (minimal differences were observed between 1-hour 64Cu-SAR-bisPSMA and 68Ga-PSMA-11 PET). The mean per-patient lesion for 64Cu-SAR-bisPSMA (24-hour imaging) was 1.26, compared to 0.48 for 68Ga-PSMA-11, with a difference of 0.78 (95% confidence interval [CI]: 0.52 – 1.04), ratio 2.63 (95% CI: 1.64 – 4.20) (primary endpoint; p < 0.0001). On a per patient level, 36% (18/50) of participants were positive on 68Ga-PSMA-11 PET/CT, compared to 78% (39/50) on 64Cu-SAR-bisPSMA PET/CT (next-day imaging). The patient-level true positive rate also favoured 64Cu-SAR-bisPSMA next-day imaging (71% vs. 29% for 68Ga-PSMA-11, against the composite reference standard). In total, 68Ga-PSMA-11 identified 24 lesions across all participants, while 24-hour 64Cu-SAR-bisPSMA imaging detected 63 lesions. The increase in the number of lesions identified by 64Cu-SAR-bisPSMA was noted in the prostatic bed region (local recurrence), pelvic/extrapelvic lymph nodes and bone.4

At 24 hours, 64Cu-SAR-bisPSMA demonstrated higher lesion uptake compared to 68Ga-PSMA-11 (median maximum standardised uptake value [SUVmax] 13.6 vs. 5.3), and lower background bladder activity (median SUVmax 12.0 vs. 34.5, respectively), improving tumour-to-background contrast. These imaging attributes likely contributed to an almost perfect agreement across the three independent blinded readers for the 64Cu-SAR-bisPSMA scans, whereas the agreement was lower for 68Ga-PSMA-11. This means the readers reached the same conclusions when assessing the 64Cu-SAR-bisPSMA scans far more often than when assessing the 68Ga-PSMA-11 scans in a blinded fashion (near perfect level of agreement for 64Cu-SAR-bisPSMA, Cohen’s Kappa 0.94 vs. 0.75 for 68Ga-PSMA-11)4.

Importantly, these imaging findings informed clinically meaningful changes in planned patient management, with a marked difference between 64Cu-SAR-bisPSMA and 68Ga-PSMA-11 (planned management changes observed in 44% of patients following 64Cu-SAR-bisPSMA imaging). The two most common modifications in treatment plan were changes from observation to active treatment (12/22) and changes in the radiation field (9/22). Active planned management increased from 66% based on 68Ga-PSMA-11 results to 90% based on 64Cu-SAR-bisPSMA findings. This highlights the potential impact of 64Cu-SAR-bisPSMA on the management of patients with BCR and at these PSA levels4.

Key data from the abstract was released in February 2026 and presented at the EAU Congress in March 2026. The manuscript was selected as an Editor’s Choice article in European Urology (impact factor of 29.7) in March 2026. The results were also showcased as a Top-Rated Oral Presentation at the EANM Annual Congress 2026 in October, highlighting the significance of its findings for the fields of urology and nuclear medicine.

About COBRA
COBRA was a Phase I/IIa, multi-centre, single arm, non-randomised, open-label study of 64Cu-SAR-bisPSMA in participants with BCR of prostate cancer and negative or equivocal findings on institutional SOC conventional imaging. The primary objectives of the trial were to investigate the safety and tolerability of 64Cu-SAR-bisPSMA as well as its ability to correctly detect recurrence of prostate cancer. Patients underwent PET/ CT scans on same-day and next-day imaging (1-4 hours and 24±6 hours post-injection, respectively), which were interpreted by three blinded central readers. To determine the efficacy of 64Cu-SAR-bisPSMA imaging, same-day and next-day imaging results of the central readers were assessed against a composite reference standard that was determined by an independent, blinded, central expert panel. The reference standard consisted of histopathology, follow-up SOC imaging and/or confirmed PSA response to focal therapy12.

Fifty-two participants with negative or equivocal SOC scans were enrolled and imaged, of whom 42 were included in the calculation of the efficacy endpoints. The median PSA at study entry was 0.9 ng/mL (range 0.25 – 17.60). The study demonstrated that 64Cu-SAR-bisPSMA was safe and effective in detecting lesions in patients with BCR of prostate cancer who were negative or equivocal on SOC imaging (e.g. bone scan, CT or PET with approved PSMA imaging agents) at screening12.

The primary efficacy endpoints were patient-level correct detection rate (CDR, defined as the proportion of true positive participants out of all scanned participants who had at least one evaluable reference standard datapoint) and region-level positive predictive value (PPV, defined as the proportion of true positive regions out of all positive regions on the 64Cu-SAR-bisPSMA PET/CT scan with corresponding evaluable reference standard). The CDR range across the central readers in patients that were negative or equivocal on SOC imaging on same-day imaging was 19.0–26.2% (95% confidence interval [CI] 8.6–42.0), increasing to 26.2–33.3% (95% CI 13.9–49.5) on next-day imaging. The region-level PPV on same-day imaging range was 39.1–44.8% (95% CI 19.7–64.3), and on next-day imaging it was 32.7–43.3% (95% CI 20.3–62.6). The CDR and PPV results were substantially impacted by the large number of lesions that were detected, but unable to be biopsied as this would not be clinically appropriate, despite these patients being negative or equivocal SOC imaging. The study had biopsies performed in 9 patients, of whom 7 (almost 80%) had a positive result based on histopathology. This trial was the first study in the BCR setting, showing such considerable effects of 64Cu-SAR-bisPSMA even in patients who had failed SOC imaging12.

64Cu-SAR-bisPSMA was able to identify approximately 91% more lesions (median increase) on next-day imaging compared to same-day imaging (ranges across the readers for the total number of lesions: 53–80 on same-day vs. 82–153 on next-day imaging). The number of lesions in the pelvic lymph node region more than doubled on next-day imaging compared to same-day imaging (median increase of 108.3% across all readers comparing same-day vs. next-day imaging). The ranges of CDR and patient-level detection rate (DR, defined as the proportion of participants with a positive 64Cu-SAR-bisPSMA PET/CT scan out of all scanned participants) were both higher on next-day imaging compared to same-day imaging. The DR range on same-day imaging was 44–58% (95% CI 30–71.8), increasing on next-day imaging to 58–80% (95% CI 43.2–90)12.

The same-day and next-day 64Cu-SAR-bisPSMA scans were compared with follow-up conventional SOC PSMA PET scans in 20 participants (13 participants with 68Ga-PSMA-11 scans and 7 with 18F-DCFPyL scans) during the follow-up period. The median time from same-day 64Cu-SAR-bisPSMA imaging to follow-up SOC PSMA PET was 73.5 (range: 29-180) days. Both same-day and next-day 64Cu-SAR-bisPSMA imaging demonstrated a higher number of PET-positive lesions in a higher proportion of patients (26 and 53 lesions in 14 and 18 participants, respectively) compared with the follow-up SOC PSMA PET (20 lesions in 12 participants), indicating earlier and improved detection of recurrent prostate cancer lesions with 64Cu-SAR-bisPSMA compared with SOC PSMA PET agents12.

Following 64Cu-SAR-bisPSMA PET imaging, investigators indicated that they would change the treatment plan of approximately half of the patients (48%). Of these patients, nearly two-thirds (62.5%) proceeded to receive systemic and/or focal therapy or biopsy. Taken altogether, the findings from the COBRA trial have important clinical implications as the localisation of recurrence may lead to different treatment pathways for these patients.

About AMPLIFY
AMPLIFY (64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants with Biochemical Recurrence of Prostate Cancer) is a non-randomised, single-arm, open-label, multi-centre, diagnostic clinical trial of 64Cu-SAR-bisPSMA PET in participants with rising or detectable PSA after initial definitive treatment at clinical sites across the US and Australia7.

The aim of this registrational study is to investigate the diagnostic ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer in men with PSA levels above 0.2 ng/mL. The study co-primary endpoints are participant-level CDR and region-level PPV assessed independently for same-day and next-day imaging (1-4 hours and approximately 24 hours post-administration, respectively)7.

AMPLIFY commenced in May 2025, seeking to enrol approximately 220 participants, and the first trial participant was imaged in the same month at XCancer with Dr Luke Nordquist (Omaha, NE). The target number of participants in the AMPLIFY study was achieved in March 2026. All trial participants are expected to complete their follow-up in the coming weeks with topline data anticipated in the first half of CY2027.

Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

On November 12, 2026 Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company advancing next-generation, half-life-extended multispecific antibodies, reported financial results for the third quarter ended September 30, 2026, and provided a business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In October, Bolt completed its acquisition of Prana Therapies in a sign-and-close, stock-for-stock reverse merger and closed a concurrent $120 million private placement financing with leading healthcare institutional investors. Following the transaction, Prana’s pipeline became the primary development focus of the company, led by flagship program PRA-216, an IL-4Rα/TSLP bispecific antibody in Phase 2 development across multiple high-value inflammatory indications. In connection with the transaction, Sheila Gujrathi, M.D., Co-Founder and former Chief Executive Officer of Prana, was appointed Chief Strategy Officer of Bolt and joined the company’s Board of Directors.

"The transaction and financing provide us with the capital and public-company foundation to advance PRA-216 and the broader INSPIRE pipeline through what we believe will be an exciting and highly data-rich period ahead," said Sheila Gujrathi, M.D., Chief Strategy Officer of Bolt Biotherapeutics. "PRA-216 is our flagship program and the first clinical validation of the INSPIRE platform. It is now in Phase 2 development in asthma, COPD and atopic dermatitis, with an additional study planned in eosinophilic esophagitis, and we expect patient proof-of-concept data across all four studies beginning in the second quarter of 2027. These studies will evaluate the potential of PRA-216 to move beyond the efficacy ceiling of single-mechanism therapies by combining complementary IL-4Rα and TSLP inhibition, while offering the potential convenience of infrequent, at-home dosing. Beyond PRA-216, we look forward to advancing additional wholly owned programs from INSPIRE as we work to build a new generation of differentiated multispecific therapies."

"Completing the Prana acquisition marks an important transformation for Bolt," said Willie Quinn, President and Chief Executive Officer of Bolt Biotherapeutics. "With a strong balance sheet, an advanced clinical program and a differentiated platform, we believe we are well positioned to execute against the important milestones ahead."

Third Quarter 2026 Financial Results

•
Cash and Financing– In October 2026, subsequent to the end of the third quarter, Bolt completed a private placement financing resulting in approximately $120 million in gross proceeds. The financing is expected to fund the company’s operations into 2028 and through multiple anticipated clinical and preclinical milestones.
•
Collaboration Revenue – Total collaboration revenue was zero for the quarter ended September 30, 2026, compared to $2.2 million for the same quarter in 2025. Revenue in the comparative periods was generated from services performed under the R&D collaborations as we fulfill our performance obligations.
•
Research and Development (R&D) Expenses – R&D expenses were $2.2 million for the quarter ended September 30, 2026, compared to $6.5 million for the same quarter in 2025. The decrease between the comparable periods was mainly due to a R&D tax incentive, a decrease in salary and related expenses primarily as a result of our restructuring, and overall lower research and development activities.
•
General and Administrative (G&A) Expenses – G&A expenses were $2.5 million for the quarter ended September 30, 2026, compared to $3.3 million for the same quarter in 2025. The decrease between the comparable periods was mainly due to a decrease in salary and related expenses primarily as a result of our restructuring as well as lower personnel expenses.
•
Loss from Operations – Loss from operations was $4.7 million for the quarter ended September 30, 2026, compared to $7.7 million for the same quarter in 2025.
Subsequent Events

•
Merger with Prana Therapies: Bolt acquired Prana on October 23, 2026 through the issuance of 430,746 shares of common stock and 16,360.929 shares of Series D non-voting preferred stock, each share of which is convertible into 1,000 shares of Common Stock. Bolt will call and hold stockholders’ meetings as soon as practicable to approve the conversion of the Series D Preferred Stock into Common Stock, and other matters as specified in the Merger Agreement. Bolt will provide the disclosures required by ASC 805, Business Combinations, once they are ready and no later than January 8, 2027.
•
Private Placement: Concurrent with the acquisition of Prana, Bolt sold and issued 13,995.311 shares of Series D Preferred Stock and accompanying warrants for aggregate gross proceeds of $120.0 million (not including any cash proceeds that may be received upon the exercise of such warrants), before deducting placement agent fees and other offering expenses.
•
Shares Outstanding: After the acquisition of Prana and the Private Placement, subject to stockholder approval of the conversion of the Series D non-voting convertible preferred stock, Bolt is expected to have approximately 34.2 million shares of common stock outstanding on an as-converted basis, before giving effect to the exercise of the PIPE warrants
•
Lease Termination: Following the October 2026 acquisition of Prana, the Chesapeake Master Lease has been terminated with an effective lease expiration date of January 1, 2027.

(Press release, Bolt Biotherapeutics, NOV 12, 2026, View Source [SID1234674667])